普洛药业连续两年入选“全国民营企业研发投入500家”榜单

Core Insights - The article highlights that Puluo Pharmaceutical has been recognized for its significant investment in R&D, being listed among the "Top 500 Private Enterprises in R&D Investment" for two consecutive years [1][2] - The company emphasizes its strategy of "innovation-driven development and talent-led innovation," maintaining a high level of R&D investment and revenue ratio [1] R&D Investment - In the first half of 2025, Puluo Pharmaceutical's R&D investment reached 360 million yuan, representing a year-on-year increase of 14.46% [1] - The R&D expense ratio was 5.95%, an increase of 1.05 percentage points compared to the same period last year [1] Hardware Development - The company is focused on enhancing its global innovative drug R&D and production service platform, which integrates the entire process from drug discovery to commercialization [1] - Puluo Pharmaceutical is optimizing its cutting-edge technology platform in key areas such as fluid chemistry, peptides, synthetic biology, and enzyme catalysis, ensuring robust hardware support for R&D innovation [1] Talent Development - Puluo Pharmaceutical has made significant progress in building a high-end R&D talent team by implementing an international recruitment system and optimizing compensation structures [2] - The company has successfully attracted experienced experts and young talents from renowned pharmaceutical companies and research institutions, forming a specialized R&D team across various disciplines [2] Future Outlook - Puluo Pharmaceutical is committed to its mission of "technology innovation serving health" and plans to continue increasing its R&D investment [2] - The company aims to further optimize its global innovative drug R&D and production service system while deepening talent development and high-end R&D capabilities [2]